Shares of Sorrento Therapeutics were pulling back after almost doubling this week on reports that the company had turned down an unsolicited and non-binding offer on Monday. The offer was made from two biopharma companies who want to acquire all outstanding stock at $3-$5 per share in cash. The offer rejected by Sorrento represented a … Continue reading “Sorrento Therapeutics Turns Down Unsolicited Offer”
